key: cord-0001771-g3a9onb5
authors: Singha, Bipradeb; Gatla, Himavanth R.; Vancurova, Ivana
title: Transcriptional Regulation of Chemokine Expression in Ovarian Cancer
date: 2015-03-17
journal: Biomolecules
DOI: 10.3390/biom5010223
sha: b81a921bc4d2223e69b7fddf4f1d2a3ba7622f92
doc_id: 1771
cord_uid: g3a9onb5

The increased expression of pro-inflammatory and pro-angiogenic chemokines contributes to ovarian cancer progression through the induction of tumor cell proliferation, survival, angiogenesis, and metastasis. The substantial potential of these chemokines to facilitate the progression and metastasis of ovarian cancer underscores the need for their stringent transcriptional regulation. In this Review, we highlight the key mechanisms that regulate the transcription of pro-inflammatory chemokines in ovarian cancer cells, and that have important roles in controlling ovarian cancer progression. We further discuss the potential mechanisms underlying the increased chemokine expression in drug resistance, along with our perspective for future studies.

Chemokines are a family of cytokines that induce chemotaxis of target cells. Though they were originally discovered for their ability to induce leukocyte migration into the infected or injured sites, more recently, it became clear that they could also promote cancer progression [1] [2] [3] [4] [5] [6] [7] [8] [9] . In addition to inducing tumor cell proliferation, angiogenesis and metastasis, chemokines and their receptors regulate tumor cell differentiation and survival. Currently, the human chemokine network includes more than OPEN ACCESS 45 known chemokines and 20 chemokine receptors. Based on the number and spacing of conserved N-terminal cysteine residues that form disulfide bonds, chemokines are divided into four groups: (X)C, CC, CXC, and CX3C [10] [11] [12] .

Epithelial ovarian cancer (EOC) is among the leading causes of cancer death in women. Since most ovarian cancers relapse and become drug-resistant, the survival rates remain low. Progression of ovarian cancer (OC) has been associated with the increased expression and release of pro-inflammatory chemokines, which contribute to ovarian cancer development through their induction of tumor cell proliferation, survival, migration, and angiogenesis [13] [14] [15] . The chemokine expression by ovarian cancer cells is controlled at several levels that include transcriptional regulation, post-transcriptional regulation and regulation of mRNA stability, translation, and mechanisms regulating the cytokine intracellular storage, transport, and release. Table 1 summarizes chemokines produced by ovarian cancer cells. Several excellent reviews have addressed the physiological and cellular functions of these chemokines in ovarian cancer [9, 16, 17] . Thus, in this review, we focus instead on the main mechanisms that regulate transcription of these chemokines in ovarian cancer cells. 

Chemokines are regulated at the transcriptional level by binding of transcription factors and repressors to gene promoter and enhancer regions. The transcription factors that control the expression of most inflammatory chemokines include the nuclear factor-țB (NFțB), activator protein-1 (AP-1) and the signal transducers and activators of transcription (STAT) family. The NFțB activity is constitutively increased in aggressive ovarian cancers, and inhibition of NFțB signaling suppresses angiogenesis and tumorigenicity of ovarian cancer cells and increases their sensitivity to chemotherapy and apoptosis [37] [38] [39] [40] . The underlying mechanisms likely involve the NFțB-regulated chemokine expression, since several studies have demonstrated that the expression of CCL2, CXCL1, CXCL2, and IL-8/CXCL8 is mediated by NFțB in ovarian cancer cells [28] [29] [30] 41] .

The increased activity of NFțB in ovarian cancer cells is mediated by enzymes of the IțB kinase (IKK) complex, which phosphorylate the NFțB inhibitory protein, IțBĮ, resulting in IțBĮ proteasomal degradation and nuclear translocation of NFțB subunits [42] [43] [44] [45] . In addition to phosphorylating IțBĮ, IKKs can also phosphorylate the NFțB subunits, particularly p65 [46] . While the cytoplasmic degradation of IțBĮ, resulting in the nuclear translocation of NFțB subunits, represents a general step in NFțB activation, the specificity of NFțB-regulated responses is mediated by the subunit composition of NFțB complexes and their post-translational modifications [47, 48] .

In addition to transcription factor binding to promoter sequences, chemokine expression is regulated by epigenetic modifications that include histone modifications as well as post-translational modifications of transcription factors, particularly the p65 subunit of NFțB. It is believed that while histone acetylation and acetylation of transcription factors induced by histone acetyl transferases (HATs) generally promotes transcriptional activation, hypoacetylation induced by histone deacetylase (HDAC) activity is associated with transcriptional repression. Since hypoacetylation of tumor suppressor genes by HDACs has been linked to tumor development, HDACs inhibitors are now being evaluated for their therapeutic effects in cancer, including ovarian cancer [49] [50] [51] . Clinical studies using HDAC inhibitors in the treatment of ovarian cancer are summarized in the recent elegant review by Khabele [52] . Numerous studies have shown that HDACs regulate chemokine expression in different cell types [53] [54] [55] [56] [57] [58] ; however, their role in the regulation of chemokine expression in ovarian cancer has yet to be documented.

Ovarian cancer tissues and ascites are characterized by decreased oxygen content, which stabilizes the Į-subunit of the transcription factor hypoxia-inducible factor-1 (Hif-1) [59] . Hif-1 responds to hypoxia by increasing the transcription of genes that promote survival in low-oxygen conditions, thus promoting angiogenesis and oncogenesis. Indeed, the increased expression of Hif-1 has been detected in epithelial ovarian cancer, and correlates with poor prognosis [60] [61] [62] . Hypoxia induces IL-8 [30], CXCL12 [63] , and CCL28 [24] expression in ovarian cancer cells. The seminal study by Xu et al. [30] demonstrated that hypoxic conditions increase the IL-8 expression in ovarian cancer cells by increasing NFțB and AP-1 binding to IL-8 promoter. The mechanisms of how hypoxia increases the NFțB-dependent IL-8 transcription involve activation of the transforming growth factor beta-activated kinase 1 (TAK1), resulting in increased IKK activation, and p65 NFțB recruitment to the IL-8 promoter [64, 65] . In addition, hypoxia induces a direct binding of Hif-1Į to the hypoxia-response element (HRE) located next to the NFțB binding site in human IL-8 promoter, resulting in the increased IL-8 expression [66] .

One of the consequences of Hif-1 activation is the increased expression of glycolytic genes, resulting in increased aerobic glycolysis, glucose consumption, and lactic acid production (Warburg effect) [67] [68] [69] . The high rate of glucose consumption and lactic acid production contributes to the acidification of the tumor environment and cancer progression. Xu et al. showed that acidic pH increases the IL-8 transcription by enhancing the binding of AP-1 and NFțB to IL-8 promoter in ovarian cancer cells [70] . In addition, in endothelial cells, lactate was shown to activate the NFțB-dependent IL-8 transcription by inducing degradation of IțBĮ [71] . The role of lactate and other metabolites of the glycolytic pathway in the regulation of pro-angiogenic chemokine expression in ovarian cancer cells is yet to be investigated, especially since recent studies have indicated high levels of aerobic glycolysis and lactate production in ovarian tumors [72, 73] .

While hyperglycemia and obesity are thought to be contributing factors to cancer development and progression, caloric restriction has been associated with reduced cancer incidence [74] [75] [76] [77] . During reduced calorie intake or exercise, the body switches to obtaining energy from fatty acid oxidation, which results in ketone bodies production. Intriguingly, the recent study by Shimazu et al. [78] has demonstrated that the ketone body ȕ-hydroxybutyrate (ȕOHB) is an endogenous and specific inhibitor of HDACs, and that administration of exogenous ȕOHB increases histone acetylation, correlating with changes in transcription. Since HDACs regulate chemokine transcription by both deacetylating histones and p65 NFțB [53] [54] [55] [56] [57] [58] , it will be important to analyze whether ȕOHB and other HDAC inhibitors regulate chemokine expression in ovarian cancer cells, and whether this is modulated by the metabolic state.

There is growing evidence that the increased chemokine expression by tumor cells modulates not only cancer development but also cancer responsiveness and resistance to chemotherapy [79] . A major contributor to the acquired chemoresistance of ovarian cancer cells is the increased expression of NFțB-dependent chemokines that is induced by the platinum-based drugs carboplatin and cisplatin, and by the mitotic inhibitors docetaxel and paclitaxel [29, [80] [81] [82] [83] . The mechanisms responsible for the increased IL-8 expression induced by paclitaxel in ovarian cancer cells involve increased expression of toll-like receptors (TLRs) and increased p65 NFțB binding to IL-8 promoter [80, 83] .

Bortezomib (BZ) is the first FDA approved proteasome inhibitor, which has shown a limited effectiveness in ovarian cancer treatment as a single agent [84] [85] [86] [87] . However, BZ has been considered in combination with cisplatin, since BZ prevents the cisplatin-induced degradation of cisplatin influx transporter, resulting in enhanced cisplatin uptake and tumor cell killing [88, 89] . We have recently shown that BZ increases expression of IL-8 and CCL2 in ovarian cancer cells, while it does not affect expression of other NFțB-dependent genes. The responsible mechanisms involve a gene specific and IKKȕ-dependent recruitment of S536 phosphorylated p65 NFțB to IL-8 and CCL2 promoters, suggesting that anti-inflammatory therapy targeting IKKȕ might increase the BZ effectiveness in ovarian cancer treatment [41] . Since approximately 50% of women diagnosed with ovarian cancer die from chemoresistant metastatic disease, understanding the molecular mechanisms by which chemotherapeutic interventions increase the chemokine expression in ovarian cancer cells should lead to the development of more effective combination strategies.

Chemokines listed in Table 1 have all been identified in ovarian cancer cells and tissues. Various online databases can be used to assess putative transcription factor binding sites. For this review, we have obtained chemokine promoter sequences from the NCBI database and used the Alggen promoter-mapping program to search for the transcription factor binding sites [90, 91] . All found putative binding sites are listed in Tables 2-5; the binding sites that have been experimentally confirmed are highlighted in bold and labeled with an asterisk. Below, we limit discussion of the transcriptional mechanisms only to the chemokines that have been experimentally confirmed in ovarian cancer cells. While the first insights into the chemokine transcriptional regulation were obtained by using in vitro electrophoretic mobility shift assays (EMSA) or overexpression experiments, chromatin immunoprecipitations (ChIP) generally provides a more realistic picture about the transcription factor binding to endogenous promoter sequences in living cells. 

CCL2 (MCP-1) is an important determinant of macrophage infiltration in ovarian tumors [92, 93] . Although CCL2 has been originally thought to have an inhibitory effect on ovarian cancer progression [94] [95] [96] , recent studies have indicated that CCL2 increases invasion of ovarian cancer cells and resistance to chemotherapy [97, 98] . The putative transcription factor binding sites identified in human CCL2 promoter are listed in Table 2 . Experimental studies demonstrated binding of NFțB, STAT1, STAT3, AP-1, and Hif-1Į to the CCL2 promoter in OC cells (Figure 1) .

Even though the NFțB binding site is located in the distal regulatory region of human CCL2 promoter (Figure 1) , several studies have demonstrated p65 NFțB involvement in the regulation of CCL2 expression in OC cells [27, 41, 99] . In addition, CCL2 expression is regulated by IKKȕ-dependent recruitment of the transcription factor EGR-1, and inhibition of IKKȕ activity decreases p65 and EGR-1 promoter recruitment and CCL2 expression [41] . Interestingly, the NFțB binding site in human CCL2 promoter has the same nucleotide sequence as the NFțB site in human IL-8/CXCL8 promoter. Curiously, both CCL2 and IL-8 are increased by paclitaxel [83] and bortezomib [41] , indicating that the paclitaxel and BZ-induced CCL2 (and IL-8) increase is promoter specific. 

where it promotes cell motility and invasiveness [100] . Phosphorylation of STAT3 at tyrosine residues 705 and 727 increases its transcriptional activity [101] . In OC cells, IL-6 [102] and M-CSF [103] induce phosphorylation and activation of STAT3, and increase the CCL2 expression. In addition to NFțB and STAT transcription factors, studies in other cell types indicated that the CCL2 expression is positively regulated by AP-1 and Hif-1Į [104] [105] [106] [107] .

Though no transcription factors have been reported to be involved in the negative regulation of CCL2 in OC cells, studies involving other cell types have reported negative regulators of CCL2. Specifically, NFțB p50/p50 homodimers, HDAC1, and the transcription factors Nrf2 and SMRT have been suggested to suppress the CCL2 expression in hepatic cells and adipocytes [108] [109] [110] .

CXCL1 (GRO-Į) contributes to ovarian cancer progression by inducing endothelial and epithelial cell proliferation and migration [25, 26] . The putative transcription factor binding sites identified in human CXCL1 promoter are listed in Table 3 . Experimental studies have demonstrated binding of the transcription factors p65 NFțB, AP-2, CCAAT displacement protein (CDP), and the stimulating protein-1 (SP-1) to the CXCL1 promoter in human cells (Figure 2 ). In ovarian cancer cells, though, the CXCL1 gene expression was found to be regulated mainly by NFțB pathway, specifically by the p65 DNA binding [25, 27, 28, 111, 112] .

In addition to the positive regulation by p65 NFțB, AP-2 and SP-1, studies using human melanocytes have indicated that the CXCL1 expression is negatively controlled by the transcriptional repressors CDP and the poly(ADPribose) polymerase-1 (PARP-1) [113, 114] . The exact mechanisms of how CDP and PARP-1 inhibit the CXCL1 expression are not fully understood; however, they likely involve displacement of trans-activating factors that bind to CXCL1 promoter, resulting in transcriptional repression. 

The putative transcription factor binding sites identified in human CXCL2 (GRO-ȕ) promoter are listed in Table 4 . However, experimental studies have demonstrated only binding of NFțB, AP-1, and STAT3 to human CXCL2 promoter (Figure 3 ). In ovarian cancer cells, the CXCL2 expression is dependent on IțBĮ [28] and IKKȕ [44] . In addition, the CXCL2 expression in OC cells is induced by TNF, and is inhibited by overexpression of the tumor suppressor p53 [115] . 

CXCL8 (IL-8), an inflammatory chemokine originally discovered as the neutrophil chemoattractant and inducer of leukocyte-mediated inflammation [1] [2] [3] , contributes to cancer progression through its induction of tumor cell proliferation, migration and angiogenesis [4] [5] [6] [7] [8] [9] . The expression levels of IL-8 directly correlate with ovarian cancer progression, and suppression of IL-8 expression inhibits angiogenesis and tumorigenicity of ovarian cancer cells [13, [116] [117] [118] . A number of studies have identified a minimal region in human IL-8 promoter that spans nucleotides -1 to -140, is necessary for IL-8 transcription, and contains binding sites for NFțB, AP-1, CCAAT enhancer-binding protein beta (C/EBP or NF-IL6), Hif-1, and NFțB-repressing factor (NRF) [119] [120] [121] [122] [123] [124] [125] [126] [127] . In addition, the IL-8 transcription in ovarian cancer cells is positively regulated by the transcription factor early growth response-1 (EGR-1) binding to IL-8 promoter, and by enzymes of IKK complex that phosphorylate both IțBĮ, leading to its cytoplasmic degradation, and p65 NFțB, resulting in its increased transcriptional activity (Figure 4) NFțB is crucial for the IL-8 expression, and regulates IL-8 in all cell types [128] . The NFțB binding sequence (GGAATTTCC) is located between -80 and -70 of the IL-8 gene [120] . In most cell types, the IL-8 transcription is regulated predominantly by p65 homodimers [37, 121, [129] [130] [131] . Phosphorylation of p65 NFțB on serines 276 and 536 increases its transcriptional activity and interaction with other transcription factor and regulators, and decreases its affinity for nuclear IțBĮ [129] [130] [131] [132] [133] . We have recently shown that in ovarian cancer cells, the IL-8 transcription is regulated by S536-p65 NFțB, IKKȕ, and EGR-1, and that proteasome inhibition developed as a strategy to inhibit NFțB-dependent transcription, paradoxically increases the IL-8 expression in ovarian cancer cells by increasing the S536-p65, IKKȕ and EGR-1 recruitment to IL-8 promoter [41] .

Adjacent to the NFțB site in the IL-8 promoter are C/EBP and Hif-1 binding sites (Figure 4 ). Even though the direct involvement of C/EBP and Hif-1 in the IL-8 regulation in ovarian cancer cells has yet to be demonstrated, the up-regulation of IL-8 expression by hypoxia in ovarian cancer cells has been well documented [30, 134] .

Transcription of IL-8 is also regulated by the transcription factor AP-1 that consists of Fos, FosB, Jun, and Jun-B subunits. Activation of AP-1 mediates the increased IL-8 expression in hypoxia, paclitaxel, and lysophosphatidic acid (LPA) treated OC cells [30, 80, 135] . Interestingly, a recent study has shown that the stress hormones norepinephrine and epinephrine enhance the IL-8 expression by a FosB-dependent mechanism [136] . Table 5 lists all putative transcription factor binding sites identified in the human CXCL8/IL-8 promoter.

Although studies from other cell types have shown that the IL-8 expression is negatively regulated by the NFțB repressing factor NRF, nuclear receptor corepressor (NCoR), the silencing mediator for retinoic acid and thyroid hormone receptor SMRT, and HDACs [54, [137] [138] [139] , the potential involvement of these corepressors in OC cells has yet to be demonstrated. Considering the important role these corepressors play in the IL-8 regulation, it will be important to elucidate their function in ovarian cancer setting.

As we continue to improve our understanding of the mechanisms regulating chemokine expression in ovarian cancer cells, our knowledge will contribute to the development of new therapeutic strategies targeting the increased chemokine expression in chemoresistant metastatic ovarian cancer. Several important questions remain to be answered: What are the specific molecular targets and mechanisms responsible for the chemokine expression induced by chemotherapeutic drugs and hypoxia? What is the role of HDACs and other transcriptional repressors in regulating the chemokine expression in ovarian cancer cells? What is the role of the metabolic state of ovarian cancer cells in regulating the chemokine expression? Answers to these questions may open new avenues for therapeutic approaches for treating ovarian cancer. 

Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils

Tumor necrosis factor-alpha, interleukin-8 and chemotactic cytokines

Human chemokines: An update

Chemokines and the molecular basis of cancer metastasis

Inflammation and cancer: Back to Virchow? Lancet

Chemokines and cancer

Cancer-related inflammation

Chemokines and chemokine receptors: New insights into cancer-related inflammation

The emerging role of CXC chemokines in epithelial ovarian cancer

Chemokines: A new classification system and their role in immunity

Structure, function, and inhibition of chemokines

The chemokine superfamily revisited

Interleukin 8: An autocrine growth factor for human ovarian cancer

The inflammatory cytokine network of epithelial cancer: Therapeutic implications

The interleukin-8 pathway in cancer

Chemokines in tumor progression and metastasis

Chemokine receptors in epithelial ovarian cancer

The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer

Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites

Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines

Role of eotaxin-1 signaling in ovarian cancer

The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells

Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers

The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer

The p65 (RelA) subunit of NFțB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression

Oxidative stress and TNFĮ induce histone acetylation and NFțB/AP-1 activation in alveolar epithelial cells: Potential mechanism in gene transcription in lung inflammation

The effect of oxidative stress on histone acetylation and IL-8 release

Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NFțB through the Akt pathway

Cigarette smoke induces proinflammatory cytokine release by activation of NFțB and posttranslational modifications of histone deacetylase in macrophages

The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NFțB

Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo

Overexpression of hypoxia-inducible factor 1Į in common human cancers and their metastases

Expression of hypoxia-inducible factor 1Į in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy

Vergote, I. HIF1Į is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer-A study of the OVCAD Consortium

CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers

Hypoxia causes the activation of NFțB through the phosphorylation of IțBĮ on tyrosine residues

Mechanism of hypoxia-induced NFțB

A novel role of hypoxia-inducible factor in cobalt chloride-and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells

Tumor cell metabolism: Cancer's Achilles' heel

Cancer cell metabolism: Warburg and beyond

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells

Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NFțB/IL-8 pathway that drives tumor angiogenesis

Metabolic changes during ovarian cancer progression as targets for sphingosine treatment

Nitric oxide is a positive regulator of the Warburg effect in ovarian cancer cells

The role of dysregulated glucose metabolism in epithelial ovarian cancer

Diabetes, cancer, and metformin: Connections of metabolism and cell proliferation

Calorie restriction and cancer prevention: A mechanistic perspective

Dietary energy balance modulates ovarian cancer progression and metastasis

Suppression of oxidative stress by ȕ-hydroxybutyrate, an endogenous histone deacetylase inhibitor

Towards understanding the role of cancer-associated inflammation in chemoresistance

Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in theinterleukin-8 promoter

Clinical update: Novel targets in gynecologic malignancies

TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer

TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer

Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum-and taxane-resistant ovarian cancer

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1

Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs

PROMO: Detection of known transcription regulatory elements using species-tailored searches

Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN

Hypoxia down-regulates MCP-1 expression: Implications for macrophage distribution in tumors

Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma

Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity

CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes

Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma

Sikic, B.I. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers

MCP-1 promotes invasion and adhesion of human ovarian cancer cells

Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium

Activated signal transducer and activator of transcription (STAT) 3: Localization in focal adhesions and function in ovarian cancer cell motility

Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T

Interleukin-6 as a therapeutic target in human ovarian cancer

Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation

Transcriptional regulation of monocyte chemotactic protein-1 release by endothelin-1 in human airway smooth muscle cells involves NFțB and AP-1

Upregulation of the chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway

High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells

Hypoxia-inducible factor-1 (HIF-1) is involved in the regulation of hypoxia-stimulated expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) and MCP-5 (Ccl12) in astrocytes

The NFțB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes

Ablation of the transcription factor Nrf2 promotes ischemia-induced neovascularization by enhancing the inflammatory response

SMRT-GPS2 corepressor pathway dysregulation coincides with obesity-linked adipocyte inflammation

Son, D. CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NFțB Activation via EGFR-transactivated Akt signaling

Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells

The role of CDP in the negative regulation of CXCL1 gene expression

Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1

Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IțB

Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth

Tumour angiogenesis regulation by the miR-200 family

Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8

Cooperative interaction of nuclear factor-kappa B-and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines

NFțB subunit-specific regulation of the interleukin-8 promoter

Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NFțB

Transcription factors NF-IL6 and NFțB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8

Synergistic transcriptional activation of the IL-8 gene by NFțB p65 (RelA) and NF-IL-6

Transcriptional inhibition of the interleukin-8 gene by interferon is mediated by the NFțB site

Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NFțB-like binding sites of the interleukin 8 gene

The NFțB repressing factor is involved in basal repression and interleukin (IL)-1-induced activation of IL-8 transcription by binding to a conserved NFțB-flanking sequence element

Multiple control of interleukin-8 gene expression

Phosphorylation of RelA/p65 on serine 536 defines an IțBĮ -independent NFțB pathway

Vancurova, I. Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IțBĮ

Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: The role of IKKĮ

Constitutive and IL-1-inducible phosphorylation of p65 NFțB at serine 536 is mediated by multiple protein kinases including IțB kinase (IKK)-Į, IKKȕ, IKKİ, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein associated factor II31-mediated IL-8 transcription

Specification of the NFțB transcriptional response by p65 phosphorylation and TNF-induced nuclear translocation of IKK epsilon

Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells

Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells

Stress effects on FosB-and IL8-driven ovarian cancer growth and metastasis

Peptide-mediated disruption of NFțB/NRF interaction inhibits IL-8 gene activation by IL-1 or Helicobacter pylori

SMRT derepression by the IțB kinase alpha: A prerequisite to NFțB transcription and survival

Mechanism of IFN-beta-mediated inhibition of IL-8 gene expression in astroglioma cells

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license

We apologize to any scientists whose work could not be cited in this review due to space limitations; Work in the Vancurova lab is supported by grant CA173452 from the National Institutes of Health.

All authors have contributed to the drafting, writing and critical revision of the manuscript, and have approved the final version of the manuscript.

The authors declare no conflicts of interest.